Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great promise when it comes to curing disease and helping patients, but also in creating value and growth. Biotech companies need to protect their scientific results and the corresponding investments with strong and durable patents. This is a complex task, with constantly evolving case law and practice on both sides of the Atlantic. In this webinar, AWA’s experts focus on how to create, defend and litigate these patents in Europe and elsewhere.
Patenting Antibody and Cell Therapies – What to Do and What Not to Do
You may also be interested in:
Companies with IP generate at least 23.8% more revenue according to latest EU report
The report ‘The Intellectual Property Rights and Firm Performance in the European Union’ was published last month and analyses
European Commission reports show misuse of divisionals can in itself contravene EU law
In November last year, I was interviewed about the European Commission’s €462.6 million fine against pharmaceutical giant Teva and
IP Enforcement Strategies: Combating Counterfeiting in Southeast Asia and China
Counterfeiting remains among the most significant threats to intellectual property rights globally, particularly in Southeast Asia and China. These